grant
Seizure, cognitive change and dementia: Understanding the use and safety of anti-seizure medications
Organization ICAHN SCHOOL OF MEDICINE AT MOUNT SINAILocation NEW YORK, UNITED STATESPosted 1 Sept 2023Deadline 31 May 2028
NIHUS FederalResearch GrantFY202521+ years old3-isobutyl GABA65 and older65 or older65 years of age and older65 years of age or more65 years of age or older65+ years65+ years oldAD related dementiaADRDActive Follow-upAdultAdult HumanAdverse effectsAgeAged 65 and OverAgingAlzheimer's and related dementiasAlzheimer's dementia and related dementiaAlzheimer's dementia or related dementiaAlzheimer's disease and related dementiaAlzheimer's disease and related disordersAlzheimer's disease or a related dementiaAlzheimer's disease or a related disorderAlzheimer's disease or related dementiaAlzheimer's disease related dementiaAmentiaAnticonvulsant AgentAnticonvulsant DrugsAnticonvulsantsAnticonvulsive AgentsAnticonvulsive DrugsApplied SkillsAttentionAttitudeAwardBehavior Conditioning TherapyBehavior ModificationBehavior TherapyBehavior TreatmentBehavioralBehavioral Conditioning TherapyBehavioral ModificationBehavioral TherapyBehavioral TreatmentBenzodiazepine CompoundsBenzodiazepinesBiometricsBiometryBiostatisticsCNS Nervous SystemCaregiver instructionCaringCentral Nervous SystemClinicalClinical TrialsCognitionCognitiveCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCohort StudiesConcurrent StudiesConditioning TherapyDataDecision MakingDegenerative Neurologic DisordersDementiaDevelopmentDiseaseDisorderDisturbance in cognitionDoseDrug MonitoringDrug PrescribingDrug PrescriptionsDrugsEmergency MedicineEpilepsyEpileptic SeizuresEpilepticsEvaluationEvidence based treatmentFoundationsFrequenciesGenerationsGeriatricsGoalsGuidelinesHealth Insurance for Aged and Disabled, Title 18Health Insurance for Disabled Title 18Health ServicesHealth Services EvaluationHealth Services ResearchHealth and Retirement StudyImpaired cognitionInsuranceInternal MedicineInterventionInvestigatorsKnowledgeLaboratoriesLearningLevetiracetamLinkLongitudinal SurveysMedical Care ResearchMedicareMedicationMedication SystemsMentorsMentorshipModelingMonitorNerve DegenerationNervous System Degenerative DiseasesNervous System DiseasesNervous System DisorderNeural Degenerative DiseasesNeural degenerative DisordersNeuraxisNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNeurologic DisordersNeurological DisordersNeurologistNeurologyNeuron DegenerationNeurontinOutcomePatient EducationPatient InstructionPatient TrainingPatientsPharmaceutical EpidemiologyPharmaceutical PreparationsPharmacoepidemiologyPhysical FunctionPhysiologicPhysiologicalPopulationPositionPositioning AttributePrevalencePrimary CareProviderQOLQualitative MethodsQuality IndicatorQuality of lifeRandomized, Controlled TrialsReactionRecommendationRecurrenceRecurrentResearch MethodologyResearch MethodsResearch PersonnelResearch ResourcesResearchersResourcesRiskSafetySamplingScienceSedation procedureSeizure DisorderSeizuresSeveritiesSocio-economic statusSocioeconomic StatusSpecialtySpinal ColumnSpineSubgroupSystemTestingTherapeuticTitle 18TitrationsTrainingTranslatingVertebral columnWorkabove age 65active followupadulthoodafter age 65age 65 and greaterage 65 and olderage 65 or olderageage of 65 years onwardaged 65 and greateraged 65+aged ≥65agesaging associatedaging relatedbackbonebehavior interventionbehavioral interventioncare coordinationcare giver educationcare giver instructioncare giver trainingcareercaregiver educationcaregiver trainingco-morbidco-morbiditycognitive changecognitive dysfunctioncognitive functioncognitive losscognitive reservecohortcomorbiditycomparativecomparative safetycoordinating caredegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdementia caredemographicsdesigndesigningdevelop therapydevelopmentaldrug epidemiologydrug/agentepilepsiaepileptogenicevidence baseexperiencefollow upfollow-upfollowed upfollowupfrailtygabapentingeriatric medicinehealth insurance for disabledhealth literacyhuman old age (65+)improvedintervention developmentmedical specialtiesmedication prescriptionmild cognitive disordermild cognitive impairmentmulti-component interventionmulti-faceted interventionmulti-modal interventionmulticomponent interventionmultifaceted interventionmultimodal interventionneural degenerationneurodegenerationneurodegenerativeneurodegenerative illnessneurological degenerationneurological diseaseneuronal degenerationolder adultolder adulthoodover 65 yearspharmacoepidemiologicpharmacoepidemiologicalpregabalinprescribed medicationprogramsqualitative reasoningrandomized control trialrecruitresearch and methodssedationseizure drugseizure medicationservices researchskillssocio-economic positionsocioeconomic positionsuccesssupport toolstherapy developmenttreatment developmenttreatment strategy≥65 years
Description preview
PROJECT SUMMARY
Guidelines for anti-seizure medications in older adult populations are incomplete or non-existent, even
though the risk of recurrent unprovoked seizures (epilepsy) in adults peaks at 80 years old. As a group, anti-
seizure medications are generally thought to be equally efficacious and medication choice should be informed
by the…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click